Project Grant F32AI188869
Award Date
5/18/25
Completion Date
11/30/26
Dollars Obligated
$148K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This Project Grant award, totaling $1,432,732, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will fund research to identify and characterize the cells that harbor persistent, non-replicating Chikungunya virus (CHIKV) RNA during the chronic stage of CHIKV-induced arthritis and myositis. The research will test the hypothesis that this persistent viral RNA activates pattern...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $782,871 in funding to the University of Colorado-Denver to investigate mechanisms by which arthritogenic alphaviruses, such as Chikungunya and Ross River viruses, evade CD8+ T cell-mediated immunity. The research aims to define how type I interferon signaling restricts myeloid cell infection and limits antigen...
This $1,108,374 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate the molecular mechanisms governing Chikungunya virus (CHIKV) binding, tropism, and pathogenesis. The research aims to define the specific heparan sulfate (HS) structures required for CHIKV attachment and infection of target cells, characterize the structural features...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $506,530.00 to support research on the role of cell-to-cell transmission in alphavirus infection and disease. The award is held by the Albert Einstein College of Medicine, with a sub-award to the University of Colorado-Denver. The research aims to define the viral envelope targets for antibody-mediated inhibition...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,341,008.00 in funding to The Washington University for research to determine the impact of stromal cell-mediated type I interferon (IFN) signaling on the pathogenesis of chikungunya virus (CHIKV) infection. The research aims to expand understanding of how stromal cells, such as fibroblasts and endothelial...
This National Institute of Allergy and Infectious Diseases (NIAID) Project Grant award under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,192,800.00 to Albert Einstein College of Medicine to characterize four novel host proteins and their roles in the alphavirus life cycle. The research aims to define the function of these host factors in the virus exit pathway and early infection steps, with the goal of identifying potential new targets for antiviral strategies...
This $218,900 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to elucidate the proteolytic determinants of flavivirus infection. The research aims to investigate the molecular factors that influence the cleavage activity of the flavivirus NS2B3 protease complex, which is essential for viral polyprotein processing and lifecycle. Specifically, the project will...
This $153,512 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand and overcome immune evasion mechanisms used by Plasmodium parasites, the causative agents of malaria. The research aims to characterize the memory B cell response to the circumsporozoite protein (CSP) antigen, which is the target of currently deployed malaria vaccines, in order to identify...
This $299,969 federal Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), seeks to evaluate a mosquito salivary protein, AGBR1, as a vaccine candidate against Chikungunya virus. The grant, awarded to L2 Diagnostics LLC, will fund comparative evaluations of recombinant protein and mRNA-LNP vaccine formulations of AGBR1 in preventing Chikungunya virus infection in murine models. The...
This $470,919 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of novel golden Syrian hamster models to study CHIKUNGUNYA virus (CHIKV) infection. The research aims to determine how type I and/or type III interferons contribute to controlling CHIKV infection, virus-induced tissue inflammation, vertical transmission, and chronic disease in hamsters. The...